Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus Biopharma (Nasdaq: ABUS) has announced its participation in the H.C Wainwright @ Home virtual fireside chat series, scheduled for December 3, 2024, at 11:00 am ET. The event will be accessible via webcast on the company's investor relations website.
Arbutus is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection. Their approach combines HBV DNA suppression, surface antigen reduction, and immune response boosting. The company's pipeline includes imdusiran (AB-729), an RNAi therapeutic showing promising functional cure rates in combination therapy, and AB-101, an oral PD-L1 inhibitor currently in Phase 1a/1b clinical trials.
Arbutus Biopharma (Nasdaq: ABUS) ha annunciato la sua partecipazione alla serie di conversazioni informali virtuali H.C Wainwright @ Home, programmata per il 3 dicembre 2024, alle 11:00 ET. L'evento sarà accessibile tramite webcast sul sito web delle relazioni con gli investitori dell'azienda.
Arbutus è una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di una cura funzionale per l'infezione cronica da virus dell'epatite B (cHBV). Il loro approccio combina la soppressione del DNA dell'HBV, la riduzione dell'antigene superficiale e il potenziamento della risposta immunitaria. Il pipeline dell'azienda include imdusiran (AB-729), una terapia RNAi che mostra tassi promettenti di cura funzionale nella terapia combinata, e AB-101, un inibitore orale di PD-L1 attualmente in sperimentazione clinica di fase 1a/1b.
Arbutus Biopharma (Nasdaq: ABUS) ha anunciado su participación en la serie de charlas informales virtuales H.C Wainwright @ Home, programada para el 3 de diciembre de 2024, a las 11:00 am ET. El evento será accesible a través de un webcast en el sitio web de relaciones con inversores de la compañía.
Arbutus es una empresa biofarmacéutica en etapa clínica centrada en desarrollar una cura funcional para la infección crónica por el virus de la hepatitis B (cHBV). Su enfoque combina la supresión del ADN del HBV, la reducción del antígeno de superficie y el aumento de la respuesta inmune. La línea de productos de la empresa incluye imdusiran (AB-729), una terapia de RNAi que muestra tasas prometedoras de cura funcional en terapia combinada, y AB-101, un inhibidor oral de PD-L1 que actualmente se encuentra en ensayos clínicos de fase 1a/1b.
Arbutus Biopharma (나스닥: ABUS)는 H.C Wainwright @ Home 가상 대화 시리즈에 참여한다고 발표했습니다. 이 이벤트는 2024년 12월 3일 오전 11:00 ET에 예정되어 있으며, 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있습니다.
Arbutus는 만성 B형 간염 바이러스(cHBV) 감염에 대한 기능적 치료제를 개발하는 데 초점을 맞춘 임상 단계의 생물 의약품 회사입니다. 이들의 접근 방식은 HBV DNA 억제, 표면 항원 감소 및 면역 반응 증대를 결합합니다. 회사의 파이프라인에는 복합 요법에서 유망한 기능적 치유율을 보이고 있는 imdusiran (AB-729)이라는 RNAi 치료제와 현재 1a/1b 단계의 임상 시험 중인 AB-101라는 경구용 PD-L1 억제제가 포함되어 있습니다.
Arbutus Biopharma (Nasdaq: ABUS) a annoncé sa participation à la série de discussions informelles virtuelles H.C Wainwright @ Home, prévue le 3 décembre 2024 à 11h00 ET. L'événement sera accessible par webcast sur le site de relations investisseurs de l'entreprise.
Arbutus est une entreprise biopharmaceutique en phase clinique axée sur le développement d'un traitement fonctionnel pour l'infection chronique par le virus de l'hépatite B (cHBV). Leur approche combine la suppression de l'ADN du HBV, la réduction de l'antigène de surface et le renforcement de la réponse immunitaire. Le pipeline de l'entreprise comprend imdusiran (AB-729), une thérapie par RNAi montrant des taux prometteurs de guérison fonctionnelle dans le cadre d'une thérapie combinée, et AB-101, un inhibiteur oral de PD-L1 actuellement en essais cliniques de phase 1a/1b.
Arbutus Biopharma (Nasdaq: ABUS) hat seine Teilnahme an der H.C Wainwright @ Home virtuellen Kaminabend-Serie angekündigt, die für den 3. Dezember 2024 um 11:00 Uhr ET angesetzt ist. Die Veranstaltung wird über ein Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein.
Arbutus ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer funktionellen Heilung für die chronische Hepatitis-B-Virus (cHBV) Infektion konzentriert. Ihr Ansatz kombiniert die Unterdrückung von HBV-DNA, die Reduktion des Oberflächenantigens und die Steigerung der Immunantwort. Die Produktpipeline des Unternehmens umfasst imdusiran (AB-729), ein RNAi-Therapeutikum, das in der Kombinationsbehandlung vielversprechende funktionelle Heilungsraten zeigt, und AB-101, einen oralen PD-L1-Inhibitor, der derzeit in klinischen Studien der Phase 1a/1b ist.
- None.
- None.
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET.
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus’ pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. Plans are underway to advance imdusiran into a Phase 2b clinical trial. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When is Arbutus Biopharma (ABUS) participating in the H.C Wainwright fireside chat?
What are the main drug candidates in Arbutus Biopharma's (ABUS) pipeline?
What is the therapeutic focus of Arbutus Biopharma (ABUS)?
How can investors access the Arbutus Biopharma (ABUS) H.C Wainwright fireside chat?
